Once daily insulin glargine may induce loss of basal insulin action in some patients with type 1 diabetes receiving basal bolus regimens: The need for twice daily glargine?

被引：0
|
作者：
Idampitiya, C
Ward, K
Curtis, C
Fernando, DJS
Idris, I
Thomson, G
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A493 / A493
页数：1
相关论文
共 50 条
  • [41] Italian experience trial for the implementation of insulin glargine in basal-bolus regimen in patients with type 1 diabetes
    Brunetti, P.
    Muggeo, M.
    Cattin, L.
    Arcangeli, A.
    Pozzilli, P.
    Provenzano, V.
    Francesconi, A.
    Calatola, P.
    Santeusanio, F.
    DIABETOLOGIA, 2007, 50 : S394 - S394
  • [42] Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial
    Koivisto, V.
    Cleall, S.
    Pontiroli, A. E.
    Giugliano, D.
    DIABETES OBESITY & METABOLISM, 2011, 13 (12): : 1149 - 1157
  • [43] Improved Glycemic Control Despite Reductions in Bolus Insulin Doses With Basal Insulin LY2605541 Compared With Basal Insulin Glargine in Patients With Type 1 Diabetes
    Rosenstock, Julio
    Bergenstal, Richard M.
    Blevins, Thomas
    Morrow, Linda
    Qu, Yongming
    Jacober, Scott J.
    DIABETES, 2013, 62 : A232 - A232
  • [44] A basal-bolus regimen of insulin glargine and insulin glulisine results in a lower rate of hypoglycaemia relative to endpoint HbA1c versus twice-daily premixed insulin in type 2 diabetes patients
    Fritsche, A.
    Larbig, M.
    Haering, H. -U.
    DIABETOLOGIA, 2010, 53
  • [45] A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes
    Bergenstal, Richard M.
    Rosenstock, Julio
    Arakaki, Richard F.
    Prince, Melvin J.
    Qu, Yongming
    Sinha, Vikram P.
    Howey, Daniel C.
    Jacober, Scott J.
    DIABETES CARE, 2012, 35 (11) : 2140 - 2147
  • [46] Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy)
    Kawaguchi, Yuji
    Sawa, Jun
    Hamai, Chie
    Nishimura, Yuri
    Kumeda, Yasuro
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) : 1527 - 1536
  • [47] Glargine vs insulatard: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - the Glargine and Aspart Study (GLASS)
    Davies, MJ
    Chatterjee, S
    Rengarajan, T
    Lawrence, IG
    McNally, PG
    DIABETOLOGIA, 2005, 48 : A329 - A329
  • [48] Comparison of Prandial AIR Inhaled Insulin Alone to Intensified Insulin Glargine Alone and to AIR Insulin Plus Intensified Insulin Glargine in Patients with Type 2 Diabetes Previously Treated with Once-Daily Insulin Glargine
    Rosenstock, Julio
    Eliaschewitz, Freddy G.
    Heilmann, Cory R.
    Muchmore, Douglas B.
    Hayes, Risa P.
    Belin, Ruth M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 : S63 - S73
  • [49] A Type 1 approach to Type 2 diabetes? A pilot study comparing traditional twice-daily insulin with basal bolus and carbohydrate counting regimens
    Charlton, J.
    Kilbride, L.
    Mackay, L.
    Douglas, S.
    McKnight, J.
    DIABETIC MEDICINE, 2007, 24 : 72 - 72
  • [50] THE DAILY REQUIREMENT OF BASAL INSULIN IN PREGNANT WOMEN WITH TYPE 1 DIABETES RECEIVING INSULIN BY THE PUMP
    Valeeva, F.
    Sharipova, Y. U.
    Alimetova, Z. R.
    Gaysina, L. R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A68 - A69
12345